APA (7th ed.) Citation

Kulshrestha, R., Rani, M., Dahiya, R., Singh, A., Doraiswamy, S., Bharadwaj, S., . . . Mishra, A. K. (2025). FGF/FGFR1,2 targeting can attenuate lung parenchymal and vascular remodeling: An opportunity for drug repurposing against chronic lung disease and post COVID‐19 sequelae. Surgical & Experimental Pathology, 8(1), 1. https://doi.org/10.1186/s42047-025-00202-7

Chicago Style (17th ed.) Citation

Kulshrestha, R., et al. "FGF/FGFR1,2 Targeting Can Attenuate Lung Parenchymal and Vascular Remodeling: An Opportunity for Drug Repurposing Against Chronic Lung Disease and Post COVID‐19 Sequelae." Surgical & Experimental Pathology 8, no. 1 (2025): 1. https://doi.org/10.1186/s42047-025-00202-7.

MLA (9th ed.) Citation

Kulshrestha, R., et al. "FGF/FGFR1,2 Targeting Can Attenuate Lung Parenchymal and Vascular Remodeling: An Opportunity for Drug Repurposing Against Chronic Lung Disease and Post COVID‐19 Sequelae." Surgical & Experimental Pathology, vol. 8, no. 1, 2025, p. 1, https://doi.org/10.1186/s42047-025-00202-7.